NCT05142696
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05142696
Title A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUT

Facility Status City State Zip Country Details
Georgetown University Lombardi Cancer Center Washington D.C. District of Columbia 20007 2197 United States Details
Advent Health Cancer Institute Orlando Florida 32804 United States Details
University Cancer and Blood Center LLC Athens Georgia 30607 United States Details
University of Kentucky Lexington Kentucky 40536 United States Details
St. Louis University St Louis Missouri 63104 United States Details
Hackensack Meridian Health Edison New Jersey 88837 United States Details
University Hospitals Of Cleveland Cleveland Ohio 44106 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Vanderbilt University Medical Ctr Nashville Tennessee 37232 United States Details
Novartis Investigative Site Innsbruck Tyrol 6020 Austria Details
Novartis Investigative Site Linz Upper Austria A 4020 Austria Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Montreal Quebec H2W 1T8 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1E2 Canada Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Olomouc 779 00 Czechia Details
Novartis Investigative Site Bron 69677 France Details
Novartis Investigative Site Lille 59000 France Details
Novartis Investigative Site Marseille 13885 France Details
Novartis Investigative Site Montpellier 34298 France Details
Novartis Investigative Site Nantes 44093 France Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Cologne North Rhine-Westphalia 50937 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Hong Kong 999077 Hong Kong Details
Novartis Investigative Site Beersheba 8457108 Israel Details
Novartis Investigative Site Haifa 3109601 Israel Details
Novartis Investigative Site Ramat Gan 5265601 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Milan MI 20133 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Amersfoort 3813 Netherlands Details
Novartis Investigative Site Utrecht 3543 AZ Netherlands Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Seoul 03722 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Salamanca Castille and León 37007 Spain Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Málaga 29010 Spain Details
Novartis Investigative Site Taichung Taiwan ROC 40201 Taiwan Details
Novartis Investigative Site Taipei 103616 Taiwan Details
Novartis Investigative Site Taoyuan District 33305 Taiwan Details
Novartis Investigative Site Guildford Surrey GU2 7XX United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field